2,3,4,6-tetrahydroxy-6,7,8,9-tetrahydro-benzocyclohepten-5-one | 83507-75-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,3,4,6-tetrahydroxy-6,7,8,9-tetrahydro-benzocyclohepten-5-one
• 英文别名: 2,3,4,6-Tetrahydroxy-6,7,8,9-tetrahydro-benzocyclohepten-5-on；Tetrahydropurpurogallin；2,3,4,6-Tetrahydroxy-6,7,8,9-tetrahydrobenzo[7]annulen-5-one
• CAS: 83507-75-9
• 化学式: C₁₁H₁₂O₅
• 分子量: 224.213
• InChiKey: VTNFTNAPMYJULI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3,4,6-tetrahydroxy-6,7,8,9-tetrahydro-benzocyclohepten-5-one 在 盐酸 、 汞 、 锌 作用下， 以 甲苯 为溶剂， 生成 1,2,3-Trihydroxy-benzosuberan
  参考文献：
  名称：

  Horner,L.; Weber,K.H., Chemische Berichte, 1962, vol. 95, p. 1227 - 1236

  摘要：

  DOI：
• 作为产物：
  描述：

  红倍酚 在 溶剂黄146 、 铂 作用下， 生成 2,3,4,6-tetrahydroxy-6,7,8,9-tetrahydro-benzocyclohepten-5-one
  参考文献：
  名称：

  207. Purpurogallin。第一部分

  摘要：

  DOI：

  10.1039/jr9480001045

文献信息

• A Novel Rearrangement of o-Nitrophenylacetic Acids
  作者：Gordon N. Walker

  DOI：10.1021/ja01629a120

  日期：1955.12
• 207. Purpurogallin. Part I
  作者：Robert D. Haworth、Barry P. Moore、Peter L. Pauson

  DOI：10.1039/jr9480001045

  日期：——
• COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS
  申请人：Watson Richard L.

  公开号：US20090274771A1

  公开（公告）日：2009-11-05

  Provided are compositions and methods for treating or preventing lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis (e.g. nose respiratory tract), and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating a lung disorder or a symptom thereof is thereby afforded. Additional aspects relate to therapeutic compositions, and combination treatment methods comprising administration of at least one electrokinetically generated fluid in combination with at least one additional therapeutic agent.
• Horner,L.; Weber,K.H., Chemische Berichte, 1962, vol. 95, p. 1227 - 1236
  作者：Horner,L.、Weber,K.H.

  DOI：——

  日期：——
• CANNON, J. G.;DEMOPOULOS, B. J., ORG. PREP. AND PROCED. INT., 1982, 14, N 5, 333-336
  作者：CANNON, J. G.、DEMOPOULOS, B. J.

  DOI：——

  日期：——